Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers - 27/10/20
pages | 8 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | ARID1A is among the most commonly mutated genes across a wide array of cancers. |
• | ARID1A deficiency is sensitive to ICB treatment. |
• | ARID1A deficiency shows predictive and prognostic value for ICB treatment. |
• | Potential targeting agents for ARID1A deficiency appear to synergize with ICB treatment. |
Abstract |
The AT-rich interaction domain 1A (ARID1A) are frequently mutates across a broad spectrum of cancers. The majority of ARID1A mutations are inactivating mutations and lead to loss expression of the ARID1A protein. To date, clinical applicable targeted cancer therapy based on ARID1A mutational status has not been described. With increasing number of studies reported that the ARID1A deficiency may be a novel predictive biomarker for immune checkpoint blockade (ICB) treatment. ARID1A deficiency would compromise mismatch repair pathway and increase the number of tumor-infiltrating lymphocytes, tumor mutation burden and expression of programmed cell death ligand 1 (PD-L1) in some cancers, which would suggested cooperate with ICB treatment. In this review, we summarize the relationship between ARID1A deficiency and ICB treatment including potential mechanisms, potential therapeutic combination, and the biomarker value of ARID1A deficiency.
Le texte complet de cet article est disponible en PDF.Keywords : ARID1A, Immunotherapy, Biomarker, Tumor immunotherapy response
Plan
Vol 130
Article 110626- octobre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?